H. Wållberg

发表

Design and evaluation of radiolabeled tracers for tumor imaging

S. Ståhl, H. Wållberg, 2013, Biotechnology and applied biochemistry.

Design and Evaluation of Radiolabeled Affibody Tracers for Imaging of HER2-expressing Tumors

H. Wållberg, H. Wållberg, 2011 .

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.

S. Ståhl, J. Löfblom, V. Tolmachev, 2014, European journal of medicinal chemistry.

Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine

Joachim Feldwisch, Vladimir Tolmachev, L. Dinkelborg, 2009, Journal of Nuclear Medicine.

Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers.

A. Orlova, H. Wållberg, H. Wållberg, 2008, Cancer biotherapy & radiopharmaceuticals.

Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors

A. Orlova, C. Widström, S. Ahlgren, 2009, Molecular Imaging and Biology.

Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

Jonas Grafström, H. Ahlzén, S. Stone-Elander, 2016, EJNMMI Research.

188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment

M. Lubberink, S. Strand, S. Ståhl, 2014, The Journal of Nuclear Medicine.

Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.

M. Brechbiel, L. Abrahmsén, V. Tolmachev, 2008, Bioconjugate chemistry.

The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy

H. Lundqvist, V. Tolmachev, A. Orlova, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging

L. Abrahmsén, V. Tolmachev, A. Orlova, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model

S. Stone-Elander, V. Tolmachev, A. Orlova, 2009, Journal of Nuclear Medicine.

Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.

S. Ståhl, F. Frejd, L. Gedda, 2012, Bioconjugate chemistry.

Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules

S. Hosseinimehr, S. Ståhl, V. Tolmachev, 2012, Amino Acids.

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels

Vladimir Tolmachev, Mattias Sandström, V. Tolmachev, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus

S. Ståhl, V. Tolmachev, A. Orlova, 2012, Tumor Biology.

Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules

S. Hosseinimehr, S. Ståhl, V. Tolmachev, 2011, Amino Acids.

Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties

S. Hosseinimehr, S. Ståhl, V. Tolmachev, 2011, The Journal of Nuclear Medicine.

Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.

Mathias Uhlén, Vladimir Tolmachev, Stefan Ståhl, 2011, Protein expression and purification.

Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

L. Abrahmsén, J. Feldwisch, V. Tolmachev, 2010, Journal of Nuclear Medicine.

Generation of tumour‐necrosis‐factor‐α‐specific affibody 1 molecules capable of blocking receptor binding in vitro

Fredrik Y Frejd, S. Ståhl, A. Jonsson, 2009, Biotechnology and applied biochemistry.

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount

Vladimir Tolmachev, Mattias Sandström, Anna Sjöberg, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically 11C-Labeled Sel-Tagged Affibody Molecule

Jonas Grafström, S. Stone-Elander, Elias S. J. Arnér, 2012, The Journal of Nuclear Medicine.